{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:35:11Z","timestamp":1753893311704,"version":"3.41.2"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Liposarcoma (LPS) is a kind of malignancy of soft tissue usually found in the retroperitoneal, limb, or neck region, and some may be detected with delayed symptoms (pain or palpable mass), and less frequently occurs in organs of the digestive system. In contrast, Dedifferentiated liposarcoma (DDLPS) is a common histological subtype of LPS. The present study reported a case of dedifferentiated liposarcoma originating in the gallbladder. Differentiated liposarcoma originating from the gallbladder is rarely reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>A 64-year-old female patient presented to our hospital with a painless abdominal mass. Abdominal computed tomography (CT) showed that the gallbladder had lost its normal shape, and a 9.1\u2005cm\u2009\u00d7\u20097.1\u2005cm\u2009\u00d7\u200912.1\u2005cm mass was seen in the area of the gallbladder fossa and the right upper abdomen below it, which had an irregular morphology, inhomogeneous density, and nodular calcification, with marked inhomogeneous enhancement on enhancement scan. Preoperative tumor markers and liver function indicators were not abnormal. With suspicion of a giant malignant tumor of the gallbladder, she underwent a cholecystectomy combined with abdominal mass resection. After surgery, the tumor and gallbladder, were completely resected, and postoperative pathological results confirmed the diagnosis of dedifferentiated liposarcoma deriving from gallbladder. After surgery, the patient and his family refused to continue treatment. After 15 months follow-up, the patient remains asymptomatic and does not show any signs of recurrence. And she is now under continued follow - up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Treatment of dedifferentiated liposarcoma is still at exploratory stage, and a lack of clinical evidence for this condition might hinder access to clinical trials and studies. Currently, the treatment of choice for dedifferentiated liposarcoma remains radical resection. In the available clinical studies, there are no robust data to support clinical use of neoadjuvant and adjuvant radiochemotherapy. As with other diseases, the use of radiotherapy and chemotherapy before and after surgery may be a potential future treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2024.1452144","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T06:21:38Z","timestamp":1731478898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Primary dedifferentiated liposarcoma of the gallbladder: a case report and literature review"],"prefix":"10.3389","volume":"11","author":[{"given":"Lan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubin","family":"Hai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoju","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11836","DOI":"10.1038\/s41598-017-12132-w","article-title":"Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard","volume":"7","author":"Livingston","year":"2017","journal-title":"Sci Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/medsci7030048","article-title":"Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in northern California","volume":"7","author":"Seto","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO classification of soft tissue tumours: news and perspectives","volume":"113","author":"Sbaraglia","year":"2021","journal-title":"Pathologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e13446","DOI":"10.1097\/md.0000000000013446","article-title":"Primary small bowel mesentery de-differentiated liposarcoma causing torsion with no recurrence for 5 years a case report and review of the literature","volume":"97","author":"Matsuo","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/his.12311","article-title":"Liposarcomas: diagnostic pitfalls and new insights","volume":"64","author":"Dei Tos","year":"2014","journal-title":"Histopathology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1007\/s00018-016-2266-2","article-title":"Liposarcoma: molecular targets and therapeutic implications","volume":"73","author":"Bill","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00000478-197912000-00004","article-title":"Liposarcoma: a study of 55 cases with a reassessment of its classification","volume":"3","author":"Evans","year":"1979","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00000478-199703000-00002","article-title":"Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation","volume":"21","author":"Henricks","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3892\/mco.2019.1882","article-title":"Dedifferentiated liposarcoma of the thyroid gland: a case report","volume":"11","author":"Kishimoto","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00428-009-0815-x","article-title":"Well-differentiated and dedifferentiated liposarcomas","volume":"456","author":"Coindre","year":"2010","journal-title":"Virchows Arch"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.2147\/OTT.S112580","article-title":"Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas","volume":"9","author":"De Vita","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/01.sla.0000086542.11899.38","article-title":"Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma","volume":"238","author":"Singer","year":"2003","journal-title":"Ann Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-020-0705-7","article-title":"Dedifferentiated liposarcoma: systemic therapy options","volume":"21","author":"Gahvari","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s13577-020-00436-5","article-title":"Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma","volume":"34","author":"Tsuchiya","year":"2021","journal-title":"Hum Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11512","DOI":"10.1200\/JCO.2018.36.15_suppl.11512","article-title":"Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: a phase 2\/3, randomized, double blind, placebo controlled crossover study","volume":"36","author":"Gounder","year":"2018","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1038\/s41467-019-13286-z","article-title":"Integrated exome and RNA sequencing of dedifferentiated liposarcoma","volume":"10","author":"Hirata","year":"2019","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/PAP.0000000000000101","article-title":"Dedifferentiated liposarcoma: updates on morphology, genetics, and therapeutic strategies","volume":"23","author":"Thway","year":"2016","journal-title":"Adv Anat Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/j.annpat.2012.07.006","article-title":"New WHO classification of tumours of soft tissue and bone","volume":"32","author":"Coindre","year":"2012","journal-title":"Ann Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.canep.2014.07.014","article-title":"The burden of rare cancer in Japan: application of the RARECARE definition","volume":"38","author":"Tamaki","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/kjm2.12295","article-title":"Dedifferentiated liposarcoma of the gallbladder","volume":"36","author":"Cheng","year":"2020","journal-title":"Kaohsiung J Med Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12957-018-1520-5","article-title":"Dedifferentiated liposarcoma of the gallbladder: first reported case","volume":"16","author":"da Costa","year":"2018","journal-title":"World J Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.asjsur.2022.08.060","article-title":"Dedifferentiated liposarcoma of the gallbladder: a rare case report","volume":"46","author":"Zou","year":"2023","journal-title":"Asian J Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.12998\/wjcc.v7.i11.1344","article-title":"Huge primary dedifferentiated pancreatic liposarcoma mimicking carcinosarcoma in a young female: a case report","volume":"7","author":"Liu","year":"2019","journal-title":"World J Clin Cases"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1007\/s00261-022-03522-4","article-title":"Pancreatic liposarcoma: a case report","volume":"47","author":"Tanabe","year":"2022","journal-title":"Abdom Radiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1016\/j.asjsur.2023.01.042","article-title":"Primary dedifferentiated liposarcoma of the pancreas: a case report","volume":"46","author":"Xiang","year":"2023","journal-title":"Asian J Surg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3760\/cma.j.cn112151-20210315-00206","article-title":"Dedifferentiated liposarcoma characterized by spindle cell rhabdomyosarcoma: report of a case","volume":"50","author":"Xue","year":"2021","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/1097-0142(19871201)60:11%3C2785::AID-CNCR2820601131%3E3.0.CO;2-O","article-title":"Dedifferentiated liposarcoma of the liver","volume":"60","author":"Kim","year":"1987","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/1097-0142(197108)28:2%3C461::AID-CNCR2820280227%3E3.0.CO;2-U","article-title":"Dedifferentiation of low-grade chondrosarcomas","volume":"28","author":"Dahlin","year":"1971","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1053\/adpa.2000.8133","article-title":"Liposarcoma: new entities and evolving concepts","volume":"4","author":"Dei Tos","year":"2000","journal-title":"Ann Diagn Pathol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1166764","DOI":"10.3389\/fsurg.2023.1166764","article-title":"Retroperitoneal undifferentiated pleomorphic sarcoma with total nephrectomy: a case report and literature review","volume":"10","author":"Yu","year":"2023","journal-title":"Front Surg"},{"key":"B31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jamcollsurg.2013.10.009","article-title":"Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery","volume":"218","author":"Keung","year":"2014","journal-title":"J Am Coll Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ejso.2015.01.012","article-title":"Metastasis in dedifferentiated liposarcoma: predictors and outcome in 148 patients","volume":"41","author":"Tirumani","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/2159-8290.CD-11-0181","article-title":"Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas","volume":"1","author":"Taylor","year":"2011","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00432-018-2777-3","article-title":"Primary anatomical site, adjuvant therapy, and other prognostic variables for dedifferentiated liposarcoma","volume":"145","author":"Gootee","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1148\/rg.291085203","article-title":"Fat-containing lesions of the retroperitoneum: radiologic-pathologic correlation","volume":"29","author":"Craig","year":"2009","journal-title":"Radiographics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clinimag.2009.12.025","article-title":"Dedifferentiated liposarcoma of retroperitoneum: spectrum of imaging findings in 15 patients","volume":"34","author":"Hong","year":"2010","journal-title":"Clin Imaging"},{"key":"B37","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/00004728-200309000-00019","article-title":"Primary dedifferentiated liposarcoma of the retroperitoneum -: prognostic significance of computed tomography and magnetic resonance imaging features","volume":"27","author":"Tateishi","year":"2003","journal-title":"J Comput Assist Tomogr"},{"key":"B38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2214\/ajr.161.1.8517290","article-title":"Dedifferentiated liposarcoma of the extremities: imaging findings in four patients","volume":"161","author":"Kransdorf","year":"1993","journal-title":"AJR Am J Roentgenol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1148\/rg.255055106","article-title":"From the archives of the AFIP - imaging of musculoskeletal liposarcoma with radiologic-pathologic correlation","volume":"25","author":"Murphey","year":"2005","journal-title":"Radiographics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jos.2016.05.006","article-title":"Clinical outcome of dedifferentiated liposarcoma in the extremities: a retrospective case series of 7 patients","volume":"21","author":"Kito","year":"2016","journal-title":"J Orthop Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1097\/01.pas.0000170343.09562.39","article-title":"MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes -: a comparative analysis of 559 soft tissue neoplasms with genetic data","volume":"29","author":"Binh","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"12420","DOI":"10.1038\/s41598-022-16455-1","article-title":"Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup","volume":"12","author":"Martinez-Monleon","year":"2022","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1097\/PAS.0b013e3181accb01","article-title":"Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma","volume":"33","author":"Chung","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/jcp.2009.070201","article-title":"Can MDM2 and CDK4 make the diagnosis of well differentiated\/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours","volume":"62","author":"Aleixo","year":"2009","journal-title":"J Clin Pathol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.soc.2016.05.007","article-title":"Liposarcoma multimodality management and future targeted therapies","volume":"25","author":"Crago","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"B46","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jso.20975","article-title":"Diagnosis and management of lipomatous tumors","volume":"97","author":"Dalal","year":"2008","journal-title":"J Surg Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","article-title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Bonvalot","year":"2020","journal-title":"Lancet Oncology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.3390\/cancers12103058","article-title":"Novel therapeutic insights in dedifferentiated liposarcoma: a role for FGFR and MDM2 dual targeting","volume":"12","author":"Dadone-Montaudi\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.6004\/jnccn.2017.0146","article-title":"Clinical practice guidelines in oncology","volume":"15","author":"Denlinger","year":"2017","journal-title":"J Natl Compr Cancer Network"},{"key":"B50","doi-asserted-by":"publisher","first-page":"102716","DOI":"10.1016\/j.ctrv.2024.102716","article-title":"Well-differentiated liposarcomas and dedifferentiated liposarcomas: systemic treatment options for two sibling neoplasms","volume":"125","author":"Kyriazoglou","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/jco.2017.74.9598","article-title":"Clinical and molecular spectrum of liposarcoma","volume":"36","author":"Lee","year":"2018","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"17588359221081073","DOI":"10.1177\/17588359221081073","article-title":"Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma","volume":"14","author":"Thirasastr","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdr485","article-title":"Advanced well-differentiated\/dedifferentiated liposarcomas: role of chemotherapy and survival","volume":"23","author":"Italiano","year":"2012","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"CD003293","DOI":"10.1002\/14651858.CD003293","article-title":"Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma","volume":"2003","author":"Bramwell","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"B55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1006959","DOI":"10.3389\/fonc.2022.1006959","article-title":"Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma","volume":"12","author":"Traweek","year":"2022","journal-title":"Front Oncol"},{"key":"B57","first-page":"5762","article-title":"Therapeutic opportunities in cancer therapy: targeting the p53-MDM2\/MDMX interactions","volume":"11","author":"Munisamy","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cancergen.2017.09.005","article-title":"High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: a cytogenomic microarray analysis of 47 cases","volume":"218","author":"Ricciotti","year":"2017","journal-title":"Cancer Genet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1634\/theoncologist.2019-0047","article-title":"Degree of MDM2 amplification affects clinical outcomes in dedifferentiated liposarcoma","volume":"24","author":"Bill","year":"2019","journal-title":"Oncologist"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1101\/gad.7.7a.1126","article-title":"THE P53 MDM-2 autoregulatory feedback loop","volume":"7","author":"Wu","year":"1993","journal-title":"Genes Dev"},{"key":"B62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molmed.2006.11.002","article-title":"MDM2 inhibitors for cancer therapy","volume":"13","author":"Vassilev","year":"2007","journal-title":"Trends Mol Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1158\/0008-5472.CAN-04-3576","article-title":"Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors","volume":"65","author":"Carvajal","year":"2005","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1158\/1078-0432.CCR-15-1522","article-title":"SAR405838: a novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma","volume":"22","author":"Bill","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7970","DOI":"10.1021\/jm901400z","article-title":"Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction","volume":"52","author":"Yu","year":"2009","journal-title":"J Med Chem"},{"key":"B66","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/med.20236","article-title":"Small molecule agents targeting the p53-MDM2 pathway for cancer therapy","volume":"32","author":"Wang","year":"2012","journal-title":"Med Res Rev"},{"key":"B68","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1158\/1078-0432.CCR-21-4243","article-title":"Correction: SAR405838: a novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma","volume":"28","author":"Bill","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.1158\/0008-5472.CAN-18-0338","article-title":"Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53-MDM2 inhibitor HDM201","volume":"78","author":"Jeay","year":"2018","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1200\/JCO.2018.36.15_suppl.11514","article-title":"A phase 1 study of MDM2 inhibitor DS-3032b in patients with well\/de-differentiated liposarcoma (WD\/DD LPS), solid tumors (ST) and lymphomas (L)","volume":"36","author":"Bauer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"12609","DOI":"10.1038\/ncomms12609","article-title":"TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma","volume":"7","author":"Jung","year":"2016","journal-title":"Nat Commun"},{"volume-title":"The role of Cdk4 in tumorigenesis and angiogenesis","year":"2008","author":"Abedin","key":"B72"},{"key":"B73","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","article-title":"Progression-Free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial","volume":"2","author":"Dickson","year":"2016","journal-title":"JAMA Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-21-1291","article-title":"Co-targeting of MDM2 and CDK4\/6 with siremadlin and ribociclib for the treatment of patients with well-differentiated or dedifferentiated liposarcoma: results from a proof-of-concept, phase Ib study","volume":"28","author":"Abdul Razak","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.3390\/cancers14112624","article-title":"Telomere as a therapeutic target in dedifferentiated liposarcoma","volume":"14","author":"Alessandrini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B76","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12885-015-1916-3","article-title":"AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas","volume":"15","author":"May","year":"2015","journal-title":"BMC Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.18632\/oncotarget.13485","article-title":"Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma","volume":"8","author":"Garg","year":"2017","journal-title":"Oncotarget"},{"key":"B78","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1073\/pnas.94.1.237","article-title":"Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor","volume":"94","author":"Tontonoz","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/ans.15348","article-title":"Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases","volume":"89","author":"Vodanovich","year":"2019","journal-title":"ANZ J Surg"},{"key":"B80","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1245\/s10434-022-12487-z","article-title":"Clinical impact of external beam radiotherapy for surgically resected primary retroperitoneal liposarcoma","volume":"30","author":"Erstad","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.3390\/cancers15225469","article-title":"Retroperitoneal soft tissue sarcoma: emerging therapeutic strategies","volume":"15","author":"de Bree","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1002\/cncr.31517","article-title":"Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma","volume":"124","author":"Wisdom","year":"2018","journal-title":"Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/cancers13020360","article-title":"Immune checkpoint inhibitory therapy in sarcomas: is there light at the end of the tunnel?","volume":"13","author":"Siozopoulou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.pathol.2017.05.003","article-title":"PD-1 and PD-L1 expression in bone and soft tissue sarcomas","volume":"49","author":"Torabi","year":"2017","journal-title":"Pathology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcancer.2017.10.001","article-title":"Emerging targets in cancer immunotherapy","volume":"52","author":"Burugu","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/gcc.22899","article-title":"Prognostic significance of the MDM2\/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma","volume":"60","author":"Yamashita","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/PAS.0000000000001436","article-title":"Prognostic value of myogenic differentiation in dedifferentiated liposarcoma","volume":"44","author":"Kurzawa","year":"2020","journal-title":"Am J Surg Pathol"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2024.1452144\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T06:21:43Z","timestamp":1731478903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2024.1452144\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":89,"alternative-id":["10.3389\/fsurg.2024.1452144"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2024.1452144","relation":{},"ISSN":["2296-875X"],"issn-type":[{"type":"electronic","value":"2296-875X"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"article-number":"1452144"}}